Abstract
The food-grade bacterium Lactococcus lactis has been extensively investigated during the last two decades as a delivery vector for therapeutic proteins, DNA and vaccine antigens. The bacterium represents a safe, genetically tractable vector capable of producing heterologous therapeutic proteins at mucosal sites. Here we review recent work in which recombinant L. lactis strains have been exploited as agents to treat inflammatory bowel disease, allergy and cancer. We also describe the ability of L. lactis to deliver proteins with adjuvant potential, vaccines and DNA and discuss the therapeutic possibilities of this approach.
Keywords: Lactococcus, vaccine, therapeutic protein, vector, delivery, immunomodulation, IBD
Current Gene Therapy
Title: Lactococcus lactis as a Cell Factory for Delivery of Therapeutic Proteins
Volume: 10 Issue: 1
Author(s): Mohammed Bahey-El-Din, Cormac G.M. Gahan and Brendan T. Griffin
Affiliation:
Keywords: Lactococcus, vaccine, therapeutic protein, vector, delivery, immunomodulation, IBD
Abstract: The food-grade bacterium Lactococcus lactis has been extensively investigated during the last two decades as a delivery vector for therapeutic proteins, DNA and vaccine antigens. The bacterium represents a safe, genetically tractable vector capable of producing heterologous therapeutic proteins at mucosal sites. Here we review recent work in which recombinant L. lactis strains have been exploited as agents to treat inflammatory bowel disease, allergy and cancer. We also describe the ability of L. lactis to deliver proteins with adjuvant potential, vaccines and DNA and discuss the therapeutic possibilities of this approach.
Export Options
About this article
Cite this article as:
Bahey-El-Din Mohammed, Gahan G.M. Cormac and Griffin T. Brendan, Lactococcus lactis as a Cell Factory for Delivery of Therapeutic Proteins, Current Gene Therapy 2010; 10 (1) . https://dx.doi.org/10.2174/156652310790945557
DOI https://dx.doi.org/10.2174/156652310790945557 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Genomics Can Advance The Potential For Probiotic Cultures To Improve Liver And Overall Health
Current Pharmaceutical Design Peripheral Benzodiazepine Receptor (PBR) New Insight in Cell Proliferation and Cell Differentiation Review
Current Clinical Pharmacology Inulin as a Delivery Vehicle for Targeting Colon-Specific Cancer
Current Drug Delivery Molecular Genetics and Epidemiology of Osteoporosis
Current Pharmacogenomics Multiple Sclerosis, Gut Microbiota and Permeability: Role of Tryptophan Catabolites, Depression and the Driving Down of Local Melatonin
Current Pharmaceutical Design Bombacaceae Between the Ethnomedical Uses and Pharmacological Evidences: A Review
The Natural Products Journal Heterogeneity Amongst 5-HT3 Receptor Subunits: Is this Significant?
Current Molecular Medicine Protein Degradation by the Ubiquitin-Proteasome Pathway and Organ Fibrosis
Current Medicinal Chemistry The Clinical and Immunological Features of Patients with Primary Antibody Deficiencies
Endocrine, Metabolic & Immune Disorders - Drug Targets Does Hypoxic Response Mediate Primary Resistance to Sunitinib in Untreated Locally Advanced Breast Cancer?
Current Cancer Drug Targets miRNAs in Gastrointestinal and Liver Cancers: Their Perspectives and Clinical Applications
Current Pharmaceutical Design Mevalonate Kinase Deficiency: Disclosing the Role of Mevalonate Pathway Modulation in Inflammation
Current Pharmaceutical Design P-Selectin Antagonism in Inflammatory Disease
Current Pharmaceutical Design Emerging Breast Cancer Biomarkers
Current Cancer Therapy Reviews Strategies for Non-Invasive Molecular Imaging of Acute Allograft Rejection by Gamma Scintigraphy and Positron Emission Tomography
Current Radiopharmaceuticals Natural Carriers for siRNA Delivery
Current Pharmaceutical Design An Overview of the Design, Development and Applications of Biodegradable Stents
Drug Delivery Letters Blind Snipers: Relevant Off Target Effects of Non-chemotherapeutic Agents in Oncology: Review of the Literature
Reviews on Recent Clinical Trials Antimicrobial Peptides Present in Mammalian Skin and Gut are Multifunctional Defence Molecules
Current Pharmaceutical Design Interleukin 10 in Antiviral Responses
Current Immunology Reviews (Discontinued)